• Subscribe
  • Login


1. A multi-arm proof of concept study of adjunctive host-directed TB therapy (TB HDT).

2. Treatment outcomes, PK and safety of a six month TB treatment regimen with once weekly high dose rifapentine and moxifloxacin in the continuation phase, in HIV-infected patients on ART.

3. Rapid detection of acquired fluoroquinolone hetero-resistance (FQ-R) in MDR-TB.

4. Imatinib dose selection for DR-TB.

5. γ9δ2 T cell protection against TB infection.